Please login to the form below
The Medicines Company
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of The Medicines Company's 2013 cardiovasular sales performance.
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
company. The company points out that its European summary of product characteristics (SmPC) lists data from APOLLO on primary and secondary endpoints, including exploratory cardiac endpoints - long term data from it ... Alnylam has three more RNAi
UK trumpets life sciences post-Brexit ‘sector deal’
Other projects highlighted in the document include a $100m contract from The Medicines Company to test a cholesterol-lowering drug at the University of Oxford’s clinical trials unit, a £40m ... This ecosystem will deliver for everyone,” he added.
The Medicines Company strengthens board of directors
He said: “ I am delighted to be joining The Medicines Company, especially at such an important time. ... Clive Meanwell, chief executive officer and director of The Medicines Company, said: “We are pleased to welcome someone of Paris’s caliber to
AZ gets EU green light for new antibiotic Zavicefta
The European Medicines Agency (EMA) cleared Zavicefta (ceftazidime and avibactam) for the treatment of serious Gram-negative bacterial infections requiring hospitalization. ... The Medicines Company also has a candidate called RPXZ7009 in phase III trials
Deal Watch May 2016
The CRL refers to a manufacturing issue. ZS-9 was acquired when the company purchased ZS Pharma for $2.7bn. ... 911. The Medicines Company/ Chiesi. Product acquisition. Acquisition of cardiovascular assets Cleviprex, Kengreal and rights to Argatroban.
1 2 3 4 5 [ Next 5 results ]
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Featured jobs
-
Business Director
-
Competitive Salary Offered
-
Medical Writer
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
-
Account Director, Medical Education
-
Salary TBC
- Global Business Development Director – Health Education
-
excellent commission
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Associate Director
-
£75, 000-90, 000
-
Account Manager / Account Director
-
Competative
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Account Director
-
Competitive Salary Offered
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Senior Account Manager
-
Competitive Salary Offered
Subscribe to our email news alerts
- Essential collaboration skills training for pharma and healthcare teams launched by Dovetail.
- Evenity back on track with FDA panel blessing in osteoporosis
- NICE gives Lilly’s Verzenios chance to compete with rivals
- J&J’s Erleada cleared for early prostate cancer in Europe
- New faces at Lucid, 90Ten and Page & Page
- 90TEN gets 2019 off to a strong start with four new hires
PMHub
BASTARD . LONDON
BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...
Latest intelligence
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
- Digital applications are transforming the market access landscape
- Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
- Escaping the spin cycle of sub-optimal launch
- ...
Quick links
Infographics
